Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.
Showing 5 of 12 posts
October 16, 2017 | Blog
October is breast cancer awareness month, and In light of our recent PDx (PD1 / PD-L1) analysis, CBPartners decided to take a closer look at the potential for these paradigm-shifting therapies to make a difference for patients diagnosed with breast cancer.
October 9, 2017 | Blog
As a class, manufacturers of PDxs (PD1s / PD-L1) are enjoying great success when it comes to marketing authorisation, with four of the five brands achieving multiple FDA and EMA approvals. CBPartners takes a closer look at the successes and failures in this highly competitive class of drugs.